FDA OKs new multiple sclerosis drug

WASHINGTON — The Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.

The twice-a-day capsules, called Tecfidera, offer a new option for multiple sclerosis, a debilitating disease in which the body attacks its own nervous system. Cambridge, Mass.-based Biogen Idec already sells two other drugs for the disease, but both require injections.

There is no cure for multiple sclerosis and most patients experience relapses of symptoms, including loss of balance, weakness in arms and legs, and blurred vision. Over time patients usually become weaker and less coordinated. More than 2 million people worldwide have the disease, with about 400,000 of them in the U.S., according to Biogen.

The FDA said it approved Tecfidera based on two studies showing patients taking the drug had fewer relapses than patients taking a dummy pill.

The approval gives Biogen a new product in an increasingly crowded field of multiple sclerosis drugs.

The biotech drugmaker already sells the once-a-week multiple sclerosis injection Avonex. It also markets the once-a-month injection Tysabri through a partnership with Elan Corp. PLC of Ireland. However, Tysabri’s severe side effects have curtailed its use.

Tecfidera is designed to be taken orally, which could make it a preferred option for patients and doctors.

A Biogen executive said Wednesday that its three drugs would be used to treat different groups of patients.

“Multiple sclerosis is a reasonably complex disease and we think there are a lot of needs out there,” said Tony Kingsely, a vice president at Biogen. “By having three drugs out there I think we can address a lot of those needs.”

Kinglsey said the company will announce the pricing of the drug when it begins shipping in the next week.

Novartis launched the first pill-based multiple sclerosis drug, Gilenya, in March 2011. Sanofi won FDA approval for a second pill, its drug Aubagio, last September.

The top-selling drug for the disease worldwide is Copaxone, which is made by Teva Pharmaceutical Industries. That injection had sales of nearly $4 billion last year, according to Teva’s latest financial report.

Avonex and Tysabri had annual sales of $2.7 billion and $1.5 billion in 2011, the most recent year for which Biogen has reported annual sales.

Biogen Idec Inc. shares rose $5.59, or 3.2 percent, to close Wednesday at $182.68.

More in Local News

Bicycle tour raises money for dialysis patients

Volunteers also shared health information and put together care packages for homeless women.

Elderly couple escape serious injuries in crash with train

The driver drove down tracks instead of a road, hitting a slow-moving train near Stanwood.

Boeing reaches out to schools

Company employees helped Everett students at recent reading and Manufacturing Day events.

5-vehicle collision sends school bus into ditch; no injuries

No students were hurt when a school bus crashed into… Continue reading

Fire crew returns early from wildfires in Northern California

Four Everett firefighters returned from battling California wildfires late Thursday… Continue reading

Theft lands former insurance salesman 50 days in jail

A former insurance salesman is expected to report to jail… Continue reading

Pair of intrepid musicians climb N. Cascades summits to play

Rose Freeman and Anastasia Allison pack their instruments up mountains for high-altitude recitals.

Everett mayoral campaign is one of the priciest ever

Many campaign donors are giving to both Cassie Franklin and Judy Tuohy.

Herald columnist Julie Muhlstein (left) and Elizabeth Reed, of Snohomish, share something humorous during an interview at Reed’s Snohomish High School Class of 1942 reunion in September 2016. Muhlstein is marking 20 years as a columnist, with about 3,000 of them published in The Herald. Counting her early days as a reporter and editor, she has been with The Herald for 36 years. (Dan Bates / Herald file)
3,000 stories in 20 years: Here are some of my favorites

As a Daily Herald columnist, I’ve met remarkable people and learned much since 1997.

Most Read